The AtonRâ Biotech 360 is a long-only, USD-based, actively managed certificate.
The strategy focuses on a newer generation of tools & diagnostics technologies, drugs, and life science services that will revolutionize the future of patient care and not only towards drug developers, which are facing heightened competition, regulatory hurdles, and pricing pressure.
Investments span throughout the entire value chain of drug development in companies with robust and versatile technology platforms that could revolutionize the future of patient care through more efficient and cheaper targeted therapies.